JHOP Articles

Original Research, Adverse Events, Radiation Therapy

Evaluation of Outcomes in Patients Who Received Bevacizumab for the Treatment of Brain Radionecrosis

Jameshia A. Below, PharmD; Alina Khan, PharmD; Amanda Brahim, PharmD, BCOP, BCPS, BCACP; Luis E. Raez, MD, FACP, FCCP; Paola Izquierdo, RN, BSN, APRN, FPBC

FDA Updates

Padcev Plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma

Original Research, Multiple Myeloma, Infusion Issues, Adverse Events

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders: A Single-Center Experience

Jung Kye, PharmD, BCOP; Samit Patel, PharmD, BCOP; Maggie Seyer, PharmD, BCPS; Eun-Jeong Kim, PharmD, MS, BCOP; Rhonda Hewitt, MSN, ANP, AOCNP; Michaela Liedtke, MD; David Iberri, MD

FDA Updates

FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma

FDA Updates

FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma

FDA Updates

FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer

FDA Updates

FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer

FDA Updates

Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer

HOPA Abstracts, Tyrosine Kinase Inhibitor

Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia